Marco Gelpi
Biographic Data
| ID | 8935166 |
|---|---|
| NAME | Marco Gelpi |
| GIVEN NAMES | Marco |
| FAMILY NAME | Gelpi |
| SIGNATURE | GELPI M |
| AFFILIATIONS | Copenhagen University Hospital – Rigshospitalet |
| ORCID | 0000-0002-2730-4376 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Nucleoside/nucleotide reverse transcriptase inhibitor-associated weight gain in people living with HIV
Weight gain effects of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in people with HIV (PWH) have been sparsely studied.Participants were enrolled in the Copenhagen Comorbidity in HIV Infection (COCOMO) study. PWH receiving a backbone of emtricitabine, or lamivudine combined with abacavir, tenofovir disoproxil, or tenofovir alafenamide were analysed. Weight gain according to ART backbone and to the third drug was analysed using a multip…
No prominent works on this page.
Nucleoside/nucleotide reverse transcriptase inhibitor-associated weight gain in people living with HIV
Weight gain effects of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in people with HIV (PWH) have been sparsely studied.Participants were enrolled in the Copenhagen Comorbidity in HIV Infection (COCOMO) study. PWH receiving a backbone of emtricitabine, or lamivudine combined with abacavir, tenofovir disoproxil, or tenofovir alafenamide were analysed. Weight gain according to ART backbone and to the third drug was analysed using a multip…
Antiretroviral therapy (1 work) · Biology (1 work) · Comorbidity (1 work) · Gene (1 work) · Genetics (1 work) · HIV-related health complications and treatments (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Nucleoside (1 work) · Nucleoside Reverse Transcriptase Inhibitor (1 work)